Two Sigma Advisers’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-129,200
| Closed | -$8.7M | – | 925 |
|
|
2025
Q4 | $8.7M | Sell |
129,200
-480,800
| -79% | -$32.3M | 0.02% | 590 |
|
|
2025
Q3 | $44.7M | Buy |
610,000
+324,600
| +114% | +$21.6M | 0.09% | 185 |
|
|
2025
Q2 | $14.8M | Sell |
285,400
-8,329
| -3% | -$474K | 0.03% | 402 |
|
|
2025
Q1 | $18.7M | Buy |
293,729
+287,829
| +4,878% | +$16.7M | 0.04% | 342 |
|
|
2024
Q4 | $282K | Buy |
+5,900
| New | +$303K | ﹤0.01% | 2002 |
|
|
2023
Q3 | – | Sell |
-144,700
| Closed | -$5.22M | – | 2467 |
|
|
2023
Q2 | $5.22M | Sell |
144,700
-298,300
| -67% | -$10.2M | 0.01% | 758 |
|
|
2023
Q1 | $16.9M | Sell |
443,000
-153,100
| -26% | -$7.18M | 0.04% | 382 |
|
|
2022
Q4 | $33.9M | Buy |
596,100
+264,500
| +80% | +$13.5M | 0.09% | 212 |
|
|
2022
Q3 | $13.1M | Sell |
331,600
-58,600
| -15% | -$2.59M | 0.04% | 427 |
|
|
2022
Q2 | $17.2M | Buy |
390,200
+384,400
| +6,628% | +$16.6M | 0.05% | 364 |
|
|
2022
Q1 | $231K | Buy |
+5,800
| New | +$207K | ﹤0.01% | 2335 |
|
|
2021
Q4 | – | Sell |
-318,120
| Closed | -$12.9M | – | 2705 |
|
|
2021
Q3 | $12.9M | Sell |
318,120
-217,700
| -41% | -$9.1M | 0.03% | 441 |
|
|
2021
Q2 | $24.3M | Buy |
535,820
+95,400
| +22% | +$4.22M | 0.06% | 288 |
|
|
2021
Q1 | $18.4M | Buy |
440,420
+25,800
| +6% | +$1.18M | 0.05% | 383 |
|
|
2020
Q4 | $17.7M | Sell |
414,620
-683,000
| -62% | -$24.6M | 0.05% | 379 |
|
|
2020
Q3 | $28.8M | Sell |
1,097,620
-367,300
| -25% | -$10.2M | 0.08% | 231 |
|
|
2020
Q2 | $39.3M | Sell |
1,464,920
-61,100
| -4% | -$1.38M | 0.12% | 193 |
|
|
2020
Q1 | $27.5M | Buy |
1,526,020
+539,700
| +55% | +$10.2M | 0.11% | 224 |
|
|
2019
Q4 | $17.5M | Buy |
986,320
+636,500
| +182% | +$11M | 0.04% | 424 |
|
|
2019
Q3 | $5.43M | Buy |
349,820
+17,100
| +5% | +$282K | 0.01% | 733 |
|
|
2019
Q2 | $5.72M | Buy |
332,720
+42,000
| +14% | +$678K | 0.01% | 778 |
|
|
2019
Q1 | $4.68M | Sell |
290,720
-164,300
| -36% | -$2.66M | 0.01% | 857 |
|
|
2018
Q4 | $6.66M | Sell |
455,020
-281,100
| -38% | -$4.48M | 0.02% | 697 |
|
|
2018
Q3 | $13.4M | Sell |
736,120
-206,400
| -22% | -$3.62M | 0.03% | 501 |
|
|
2018
Q2 | $15.9M | Sell |
942,520
-151,000
| -14% | -$2.86M | 0.04% | 446 |
|
|
2018
Q1 | $21.4M | Buy |
1,093,520
+392,800
| +56% | +$7.61M | 0.06% | 386 |
|
|
2017
Q4 | $14.2M | Buy |
700,720
+573,100
| +449% | +$10.5M | 0.04% | 491 |
|
|
2017
Q3 | $2.22M | Buy |
127,620
+97,800
| +328% | +$1.32M | 0.01% | 1146 |
|
|
2017
Q2 | $382K | Buy |
29,820
+17,220
| +137% | +$230K | ﹤0.01% | 1884 |
|
|
2017
Q1 | $163K | Buy |
+12,600
| New | +$159K | ﹤0.01% | 2232 |
|
|
2016
Q1 | – | Sell |
-15,920
| Closed | -$276K | – | 2073 |
|
|
2015
Q4 | $276K | Sell |
15,920
-31,504
| -66% | -$502K | ﹤0.01% | 1553 |
|
|
2015
Q3 | $648K | Buy |
47,424
+33,304
| +236% | +$669K | ﹤0.01% | 1184 |
|
|
2015
Q2 | $319K | Buy |
+14,120
| New | +$248K | ﹤0.01% | 1595 |
|
Other funds holding HALO
VCM
VPM
Two Sigma Advisers's HALO Position: Q1 2026 in Review
Two Sigma Advisers sold out of Halozyme (HALO) in Q1 2026, closing a stake of 129,200 shares — an estimated $8.7M sold.
Two Sigma Advisers first reported a position in HALO in Q2 2015 and held it in 33 quarters. The position peaked at $44.7M in Q3 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.
- Two Sigma Advisers reported no remaining Halozyme position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 129,200 Halozyme shares in Q1 2026, an estimated $8.7M.
- Two Sigma Advisers first reported a position in Halozyme in Q2 2015 and held it in 33 quarters.
- Two Sigma Advisers's Halozyme position peaked at $44.7M in Q3 2025.
- 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.